Actively Recruiting
Phase 3 Trial of Weekly Canvuparatide Injection Compared to Placebo in Adults with Hypoparathyroidism
Led by MBX Biosciences · Updated on 2026-07-13
160
Participants Needed
2
Research Sites
82 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the safety and effectiveness of canvuparatide as a once-weekly treatment for adults with hypoparathyroidism, a condition where the body produces insufficient parathyroid hormone HypoPT. This phase 3 trial compares canvuparatide to a placebo to better understand its effects in this patient population. Participants receive canvuparatide or placebo as a single-use drug-device combination product. Each injection delivers 1 mL of the drug or placebo via a manual subcutaneous injection once weekly. The study includes a randomized, parallel design where participants are assigned to either the canvuparatide or placebo group. Throughout the study, participants are monitored for 26 weeks to measure how many respond to treatment based on key criteria. Researchers will evaluate safety and efficacy during this period. The trial involves regular assessments including blood tests to monitor serum calcium and hormone levels. Participation lasts until study completion in August 2029, with primary outcomes assessed at 26 weeks.
CONDITIONS
Brief Title
A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism
Research Team
S
Salomon Azoulay, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
